A novel triple-knockout allogeneic BCMA CAR T cell therapy (CT0590) in multiple myeloma: preclinical and phase I study - PubMed
5 hours ago
- #CAR T cell therapy
- #Multiple myeloma
- #Allogeneic immunotherapy
- A novel triple-knockout allogeneic BCMA CAR T cell therapy (CT0590) combines BCMA targeting with NKG2A CAR to counter host natural killer (NK) cell attacks.
- Preclinical studies showed CT0590 resisted NK cell-mediated killing and exhibited strong antitumor activity in vivo.
- A first-in-human phase I study enrolled five patients with relapsed/refractory multiple myeloma or primary plasma cell leukemia.
- CT0590 was well-tolerated with no dose-limiting toxicities, treatment-related deaths, or graft-versus-host disease.
- Three patients achieved confirmed responses, including two with stringent complete responses lasting over 20 months.
- Responders demonstrated robust expansion of universal CAR T cells and higher baseline NKG2A expression on NK cells.
- The CAR-NKG2A technology may overcome host-versus-graft reaction, especially in patients with elevated NKG2A expression.